Page 39 - Read Online

Page 12 of 12 Mathias-Machado et al. Hepatoma Res 2021;7:67 https://dx.doi.org/10.20517/2394-5079.2021.84

35. Jianyong L, Jinjing Z, Wentao W, et al. Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma:
a single center analysis. Ann Hepatol 2014;13:394-402. PubMed
36. Zhang Z, Wu M, Liu Q. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after
hepatectomy for hepatocellular carcninoma. Zhonghua Zhong Liu Za Zhi 1999;21:214-6. PubMed
37. Monden M, Okamura J, Sakon M, et al. Significance of transcatheter chemoembolization combined with surgical resection for
hepatocellular carcinomas. Cancer Chemother Pharmacol 1989;23 Suppl:S90-5. DOI PubMed
38. Qi X, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre- and post-operative transarterial
chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2015;6:36838-
59. DOI PubMed PMC
39. Zhang Y, Huang G, Wang Y, et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients
downstaged by transarterial chemoembolization? Oncologist 2016;21:1442-9. DOI PubMed PMC
40. Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with Yttrium-90 for the treatment of hepatocellular
carcinoma. Adv Ther 2016;33:699-714. DOI PubMed PMC
41. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar
yttrium-90 radioembolization. Ann Surg Oncol 2009;16:1587-96. DOI PubMed
42. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY
study. Hepatology 2021. DOI PubMed
43. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association;
Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment
of hepatocellular cancer: expert consensus statement. HPB (Oxford) 2010;12:313-20. DOI PubMed PMC
44. Li S, Zhong C, Li Q, et al. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable
BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: an interim analysis of a multi-center, phase 3, randomized,
controlled clinical trial. JCO 2021;39:4008. DOI
45. Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma [abstract]. Proceedings of the
American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer
Res 2021;81(13_Suppl):Abstract nr CT182. DOI
46. Pinato DJ, Cortellini A, Pai M, et al. PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection
for hepatocellular carcinoma. J Clin Oncol 2021;39:e16131. DOI PubMed PMC